The impact of patent ductus arteriosus in neonates with late onset sepsis: a retrospective matched-case control study

Pediatr Neonatol. 2012 Oct;53(5):309-14. doi: 10.1016/j.pedneo.2012.07.006. Epub 2012 Aug 21.

Abstract

Background: Late-onset sepsis (LOS) in neonates with patent ductus arteriosus (PDA) may predispose them to more complicated hospital courses. The objective of this study was to determine the incidence, the distribution of pathogens, and the clinical features of LOS in neonates with PDA and analyze their outcomes.

Methods: The medical records were reviewed retrospectively of infants with PDA and LOS who were hospitalized in NICUs of Chang Gung Children's Hospital between January 2003 and December 2009. The clinical features of these infants were compared with a group of gestational age and birth body weight-matched neonates with LOS during the same period.

Results: During this period, 224 neonates were found to have at least one event of blood-culture proven LOS and 79 (35.3%) were documented to have PDA. Although most LOS episodes (85/104, 81.7%) in neonates with PDA occurred after closure of PDA, neonates with PDA had a significantly higher rate of bronchopulmonary dysplasia (81.0% vs. 61.0%, p = 0.002) and a relatively higher rate of recurrent sepsis (25.3% vs. 15.2%, p = 0.079) than those without PDA. Longer durations of ventilator support and hospital stay were also noted in neonates with PDA as compared to those without (p = 0.001 and 0.005, respectively).

Conclusion: In neonates with LOS, the presence of PDA, even though it is aggressively treated with indomethacin or surgical intervention, may still contribute to the complexity of hospitalization. Close monitoring and aggressive treatments are warranted in these neonates with PDA.

Publication types

  • Comparative Study

MeSH terms

  • Age Factors
  • Bronchopulmonary Dysplasia / complications*
  • Bronchopulmonary Dysplasia / diagnosis
  • Bronchopulmonary Dysplasia / therapy
  • Case-Control Studies
  • Databases, Factual
  • Ductus Arteriosus, Patent / complications*
  • Ductus Arteriosus, Patent / diagnosis
  • Ductus Arteriosus, Patent / therapy*
  • Female
  • Follow-Up Studies
  • Hospital Mortality / trends
  • Humans
  • Indomethacin / therapeutic use
  • Infant, Newborn
  • Intensive Care Units, Neonatal
  • Length of Stay
  • Ligation / methods
  • Male
  • Retrospective Studies
  • Risk Assessment
  • Sepsis / etiology*
  • Sepsis / microbiology
  • Sepsis / mortality*
  • Severity of Illness Index
  • Sex Factors
  • Survival Rate
  • Time Factors

Substances

  • Indomethacin